STOCKHOLM, Sweden, May 14, 2026 — AtrimusRx has established extemporaneous compounding capabilities incorporating additive manufacturing (3D printing) as part of a validated pharmaceutical manufacturing process, becoming the first community pharmacy operator in Sweden to implement the technology within outpatient pharmacy practice.
The technology enables personalized medicine manufacturing in situations where commercially available strengths and dosage forms are insufficient to meet individual patient needs. This is particularly relevant in pediatric care, where the lack of child-appropriate medicines remains a longstanding clinical challenge.
Addressing the shortage of pediatric formulations
For many pediatric patients, suitable dosage strengths and formulations are not commercially available. As a result, adult medicines often need to be manipulated in hospitals, pharmacies, or at home — tablets are split or crushed, capsules opened, and contents mixed with food or liquids in order to achieve the prescribed dose.
Such handling may introduce dosing variability and, in some cases, shifts responsibility for dose accuracy from the medicinal product itself to healthcare professionals or caregivers.
AtrimusRx’s compounding manufacturing platform enables medicines to be produced directly according to prescription requirements, eliminating the need for subsequent manipulation. Treatment can therefore be adapted to the patient, rather than forcing the patient to adapt to the limitations of standardized products available on the market.
The compounding activities are conducted within the Atrimus Px™ framework.
Atrimus Px — Precision medicine in clinical practice
Atrimus Px™ (Prescription Precision) is AtrimusRx’s framework for precision-based pharmaceutical compounding, where medicines are tailored to the patient’s individual clinical requirements — including age, body weight, and prescribed dose — with a strong focus on quality assurance, process control, and patient safety.
The platform enables prescription-driven dose individualization across narrow dosing intervals, starting from 2 mg and with dose adjustments at quarter-milligram increments in low-dose ranges. This is particularly relevant in treatments where small variations in dose may have significant clinical implications.
The technology also enables gradual dose titration over time, including dose escalation or tapering regimens, allowing individualized treatment schedules to be incorporated within the same treatment series and packaging configuration.
In certain applications, multiple active pharmaceutical ingredients may also be combined into a single dosage form, polypill , potentially simplifying complex treatment regimens and improving adherence.
Within veterinary medicine, formulations can additionally be adapted with respect to both palatability and dosing, which may be critical for treatment compliance.
Strengthening pharmaceutical supply resilience
The type of localized, patient-specific manufacturing established by AtrimusRx is not only relevant at the individual patient level, but may also contribute to greater resilience within the broader pharmaceutical supply chain.
AtrimusRx is a partner in RoboPharma – Agile Pharmaceutical Manufacturing, a European research and development initiative co-funded by the European Union through the EU4Health programme.
The project aims to develop decentralized pharmaceutical manufacturing solutions for pharmacies and hospital pharmacies, integrating technologies such as 3D-inspired robotic dosing, AI-driven analytics, and automated pharmaceutical workflows.
Localized manufacturing closer to the point of care may play an important role during crises, pandemics, and disruptions in global supply chains, complementing existing pharmaceutical distribution systems and improving healthcare preparedness.
About AtrimusRx
AtrimusRx is a Swedish pharmaceutical company holding both wholesale distribution and community pharmacy licenses, specialized in addressing medicine shortages through the import and distribution of medicine from Europe and US, as well as extemporaneous pharmaceutical compounding within the Atrimus Px™ framework.
The company operates with a strong focus on regulatory compliance, pharmaceutical quality assurance, and patient safety. For more information, visit https://atrimusrx.com.
